• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

DreaMed Launches Virtual Diabetes Clinic to Help Type-1 Diabetics Control Their Condition in Quarantine

by Jasmine Pennic 04/15/2020 Leave a Comment

DreaMed Launches AI-Powered Virtual Clinic to Help Type-1 Diabetics Control Their Condition in Quarantine

What You Should Know:

– As COVID-19 spreads, DreaMed Diabetes unveils virtual diabetes clinic software to treat people with type 1 diabetes remotely.

– The virtual clinic utilizes Dreamed Diabetes’ AI-powered solution, to improve the insulin management treatment by analyzing the patient’s insulin and glucose data in the platform’s algorithm and to remotely advise doctors on treatment.

– According to the CDC people with chronic medical conditions, including diabetes, have a higher risk in complications should they contract the virus. As a result, patients with diabetes have been forced to skip routine visits with healthcare professionals and neglect their treatment.


As the world is scrambling to stop the spread of corona and save lives, hospitals are flooded, and medical staff are overwhelmed, leaving limited resources for treating people who are already living with chronic diseases. DreaMed Diabetes Ltd., the Israeli-based developer of personalized diabetes management solutions announces the launch of a virtual diabetes clinic to treat people with type 1 diabetes remotely. Virtual clinics give people with type 1 diabetes access to medical professionals ensuring treatment remains unaffected by widespread COVID-19-induced quarantines.

As of March 2020, COVID-19 has struck at least 150 countries and infected more than 1,000,000 people, according to WHO figures. Although most healthy people might find themselves at low risk for complications by contracting COVID-19, others are far more vulnerable. The CDC reported that people with chronic medical conditions, including diabetes, are at greater risk of complications should they contract the virus, and as a result, patients with diabetes have been forced to skip routine visits with healthcare professionals and neglect their treatment. DreaMed Diabetes remote-care virtual clinic assists people with diabetes in these difficult circumstances.

AI-Powered Virtual Clinic

DreaMed virtual diabetes clinic enables people with diabetes to receive easy, reliable treatment from a distance, allowing them to stay safe from potential infection in public areas. A virtual clinic service will utilize the DreaMed Advisor decision support technology to improve the insulin management treatment of patients.

DreaMed Advisor is an advanced decision-support tool, which generates insulin-delivery recommendations by analyzing the patient’s insulin and glucose data in the platform’s algorithm. Advisor applies event-driven adaptive learning to refine its understanding for each individual case. The solution, which was evaluated at a multi-center study at Joslin Diabetes Center, the University of Florida, Yale University, and Barbara Davis Center for Diabetes, provides recommendations to the healthcare provider on how to optimize a patient’s insulin pump settings for basal rate, carbohydrate ratio, and correction factor (insulin sensitivity). 

“We are very proud to be launching our virtual clinic, continuing our mission to provide healthcare professionals with a reliable, automated decision-support tool that empowers every patient with the best care possible,” says DreaMed Co-Founder and CEO Eran Atlas. “With the coronavirus pandemic sweeping across the globe, we realize more than ever the need to have remote, telemedicine treatment options to ensure as many people as possible, especially those with diabetes, are safe from potential infection and have access to the care they need.”

Tagged With: AI, Coronavirus (COVID-19), decision support, diabetes, Diabetes Management, DreaMed Diabetes, glucose data, insulin, Israeli digital health startups, Personalized Diabetes, risk, telemedicine, type 1 diabetes, Virtual Clinics

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Most Popular

Survey: Clinician Burnout Is A Public Health Crisis Demanding Urgent Action

17 Execs Share How Health IT Can Address Clinician Burnout, Staffing, & Capacity

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Northwell Health Extends Contract with Allscripts Sunrise Platform Through 2027

Northwell to Deploy Epic Enterprise EHR Platform Across System

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Pfizer Acquires Seagen for $43B to Tackle Cancer

Pfizer Acquires Seagen for $43B to Tackle Cancer

5 Key Trends Driving Purchasing Decisions in Healthcare IT

5 Key Trends Driving Purchasing Decisions in Healthcare IT

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Dr. Arti Masturzo

Q/A: Dr. Masturzo Talks Addressing Food Insecurity with Patients

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |